| | First author (year, area) | Study design | Age | Cancer types | No. of patients | Electric power (W: watt) | Argon gas flow rate (L/min) | Rate of complication | Frequencies of session | Rate of hemostasis | Follow-up (m: month) | Loss-up |
| | Higuera (2004, Spain) | Retrospective | 67.8 (58–76) | Cervical (1), endometrial (6), >and prostate (3) cancer | 10 | 60 | 1.5–2 | 0.0% | 1.9 (1–4) | 78.6 | 31.8 m (10–45 m) | 0 | | Alfadhli (2008, Kuwait) | Prospective | 74.7 | na | 14 | 45–50 | 1.2–2 | 14.3% | 1.78 | 85.7 | 3 m | 0 | | Alvaro (2011, Mexico) | Prospective | 59.3 ± 12 | na | 14 | 60 | 1.6 | 35.7% | 3 ± 1 | 92.6 | 3 m | 0 | | Ben (2004, France) | Prospective | 73.1 (53–86) | Prostate (19), anal (4), uterine (3), and rectal (1) cancer | 27 | 40–50 | 0.8–1 | 18.5% | 2.66 (1–7) | 92.9 | 13.6 m (3–31 m) | 0 | | Canard (2003, France) | Prospective | 70.7 (58–85) | Prostate (23), uterine (4), cervical (1), and squamous-cell anus (1) cancer and uterine (1) sarcoma | 30 | 42 (30–80) | 1.5 (0.8–1.2) | 26.7% | 69, 2.3 (1–5) | 95.2 | 1–35 m | 2 | | Chruscielewska (2013, Poland) | Prospective | 65.5 ± 10.9 | Cervical (16), endometrial (17), prostate (28), and rectal (1) cancer | 62 | 25–40 | 1.5–2/1–1.5 | 58.1% | 2 (1–3) | 91.7 | 52 weeks | 0 | | Chutkan (1997, USA) | Prospective | 72 (64–85) | Prostate (10) and uterine (2) cancer | 12 | na | na | 0.0% | 1 (1-2) | 97.9 | 6.6 m (3–13 m) | 0 | | Dees (2006, Netherlands) | Prospective | 73.6 (59–89) | Prostate (45), urinary bladder (4), and uterine cervix (1) cancer | 50 | 50 | 2 | 2.0% | 3 (1–6) | 100 | na | 2 | | Fantin (1999, Switzerland) | Retrospective | na | Prostate (6) and endometrial cancer (1) | 7 | 60 | 3 | 0.0% | 2 (2–4) | 90 | 24 m (18–24 m) | 0 | | Hortelano (2014, Spain) | Retrospective | 70 (56–78) | Prostate cancer | 30 | 50 | 1.8 | 6.67% | 3 | 76.7 | 14.5 m (2–61 m) | 0 | | Kaassis (2000, France) | Retrospective | 73.5 (62–80) | Prostate (15) and uterine (1) cancer | 16 | 40 | 0.6 | 31.3% | 3.7 | 93.8 | 10.7 m (8–28 m) | 0 | | Karamanolis (2009, Greece) | Prospective | 68.4 (45–86) | Prostate cancer | 56 | 40 | 2 | 5.4% | 2 (1–8) | 89.3 | 17.9 m (12–33 m) | 0 | | Latorre (2008, Spain) | Prospective | 70.9 ± 7.38 | na | 38 | 50–60 | 1.4–1.8 | 0.0% | 3.6 ± 2.7 | 86.8 | 28.5 ± 3.9 m | 0 | | Lenz (2011, Brazil) | Prospective | 70.4 ± 11.1 | Prostate (8), cervical (5), and endometrial (2) cancer | 15 | 40 | 1 | 40% | 3.7 ± 1.7 | 93.3 | 12.5 m (2–30 m) | 0 | | Lpoez (2010, Mexico) | Retrospective | 64 (25–80) | Cervicouterine (5), endometrial (2), vaginal (2), prostate (9), and colorectal (1) cancer | 19 | 40–50 | 1–1.5 | 5.3% | 2 (1–7) | 94.7 | 29 m (1–93 m) | 0 | | Onoyama (2011, Japan) | Prospective | 74 ± 5.5 | Prostate cancer | 24 | 30–40 | 1 | 0.0% | (1–7) | 100 | 23.5 m (1–53 m) | 0 | | Rolachon (2000, France) | Prospective | 70.3 ± 10 | Prostate (11) and endometrial (1) cancer | 12 | 50 | 1 | 25.0% | 2.8 ± 0.8 | 91.7 | 6 m | 0 | | Rotondano (2003, Italy) | Prospective | 69.2 (22–81) | Endometrial (13), cervical (6), and prostate (5) cancer | 24 | 40 | 0.8–1.2 | 25.0% | 69, 2.5 (1–6) | 91.7 | 41 m (24–60 m) | 0 | | Sait (2013, Turkey) | Retrospective | 61 | Prostate (6), rectum (2), cervix (12), and endometrium (1) cancer | 21 | 50 (40–60) | 1.5 (1.2–2) | 23.8% | 3 (1–11) | 85.7 | 34.6 m | 0 | | Samy (2012, Egypt) | Prospective | na | na | 23 | 40–50 | 0.8–1.0 | 0.0% | na | 73.9 | 37 m (6–84 m) | 0 | | Sarah (2001, France) | Prospective | 73 ± 3 | Prostate (9), uterine (1), and rectal (1) cancer | 11 | 50 | 0.8–2 | 63.6% | 3.2 ± 0.4 | 100 | 19 ± 2 m | 0 | | Sato (2011, Japan) | Prospective | 72 (35–83) | Prostate (46) and cervical (19) cancer | 65 | 40 | 1.2 | 18.5% | 2 (1–5) | 93.8 | 34.6 m (3.6–121.1 m) | 0 | | Sebastian (2004, Ireland) | Prospective | 69 (53–77) | Prostate (23) and bladder (2) cancer | 25 | 30 (25–50) | 1.5 | 0.0% | 1 (1–4) | 84 | 14 m | 0 | | Silva (1999, Portugal) | Prospective | 65 (42–77) | Cervical (17), endometrial (7), and prostate (4) cancer | 28 | 50 | 1.5 | 10.8% | 2.9 (1–8) | 96.4 | 10 m (1–15 m) | 0 | | Smith (2001, USA) | Prospective | na | Prostate cancer | 7 | 40–45 | 1.6 | 0.0% | 1–3 | 71.4 | 4–13 m | 0 | | Swan (2010, Australia) | Prospective | 72.1 (51–87) | Prostate (45), uterine (2), cervical (2), and vaginal (1) cancer | 50 | 50 | 1.4–2.0 | 36.0% | 1.36 (1–3) | 98 | 20.6 m (5–48 m) | 1 | | Takemoto (2012, Japan) | Prospective | na | Prostate cancer | 12 | 30–40 | 1 | 0.0% | (1–3) | 83.3 | 35 m (12–69 m) | 0 | | Tam (2000, Australia) | Retrospective | na | Prostate (14) and cervical (1) cancer | 15 | 60 | 2 | 13.3% | 2 (1–4) | 100 | 24 m (8–35 m) | 0 | | Tjandra (2001, Australia) | Prospective | 73 (62–78) | Prostate (10) and cervix (2) cancer | 12 | 40 | 1.5 | 0.0% | na | 50 | 11 m (4–17 m) | 0 | | Venkatesh (2002, USA) | Prospective | 64–83 | na | 40 | 40–60 | 1.5 | 0.0% | na | 97.5 | 3–30 m | 0 | | Villavicencio (2002, USA) | Prospective | 72.6 (58–86) | Prostate (15), endometrial (4), sacral chondroma (1), and cervical (1) cancer | 21 | 45–50 | 1.2–2 | 19.0% | 1.7 (1–4) | 100 | 10.5 m (1–29 m) | 0 | | Yeoh (2013, Australia) | Prospective | 73 (49–87) | Prostate cancer | 17 | 60–80 | 2 | 0.0% | 2 | 94.1 | 110 m (29–170 m) | 0 | | Zinicola (2003, Italy) | Retrospective | 68 (30–80) | Prostate (8), cervical (4), and bladder (2) cancer | 14 | 65 | 2 | 7.1% | 2.0 (1–4) | 83.3 | 19 m (5–41 m) | 2 |
|
|
